Letter
Medicine, General & Internal
Ahhyung Choi, Yunha Noh, So-Hee Park, Seung-Ah Choe, Ju-Young Shin
Summary: This cohort study aims to investigate whether the use of proton pump inhibitors during pregnancy is associated with the incidence of preeclampsia.
Letter
Medicine, General & Internal
Ahhyung Choi, Yunha Noh, Dong Keon Yon, Ju-Young Shin
Summary: This cohort study investigates the potential link between prenatal exposure to proton pump inhibitors and the risk of low birth weight.
Article
Medicine, General & Internal
Salman Hussain, Ambrish Singh, Benny Antony, Jitka Klugarova, M. Hassan Murad, Aarthi S. Jayraj, Alena Langaufova, Miloslav Klugar
Summary: This study evaluates the association between the use of proton pump inhibitors (PPIs) and the risk of preeclampsia in pregnant women. The findings suggest that the use of PPIs during pregnancy significantly increases the risk of preeclampsia, although the increase is minimal in absolute terms. However, there is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Esmee M. Breddels, Johanna Simin, Romina Fornes, Helene Lilja Engstrand, Lars Engstrand, Robin Bruyndonckx, Nele Brusselaers
Summary: This study found that the use of proton pump inhibitors during pregnancy is associated with an increased risk of pre-eclampsia, gestational diabetes, preterm birth, and being born small for gestational age, while it is associated with a decreased risk of being born large for gestational age.
Editorial Material
Oncology
Courtney M. Richman, David A. Leiman
Summary: Proton pump inhibitors (PPIs) are commonly used for digestive diseases, but there is conflicting data on the association between PPI use and gastric cancer risk. A pooled case-control study found that short-term PPI use was associated with increased risk of gastric cancer, but long-term use did not show this association. This study provides reassurance to patients and clinicians that long-term PPI use does not significantly increase gastric cancer risk.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Article
Rheumatology
Shahab Abtahi, Johanna H. M. Driessen, Andrea M. Burden, Patrick C. Souverein, Joop P. van den Bergh, Tjeerd P. van Staa, Annelies Boonen, Frank de Vries
Summary: The simultaneous use of oral glucocorticoids (GCs) and proton pump inhibitors (PPIs) increases the risk of osteoporotic fractures in patients with rheumatoid arthritis (RA), whereas the risk is relatively lower when GCs or PPIs are used alone. Among patients using both oral GCs and PPIs, the risk of fractures does not increase with higher PPI daily dose or duration.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Gastroenterology & Hepatology
Raaj S. Mehta, Bharati Kochar, Zhen Zhou, Jonathan C. Broder, Paget Chung, Keming Yang, Jessica Lockery, Michelle Fravel, Joanne Ryan, Suzanne Mahady, Suzanne G. Orchard, John J. Mcneil, Anne Murray, Robyn L. Woods, Michael E. Ernst, Andrew T. Chan
Summary: This study investigated the associations of proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) use with dementia and cognitive decline. The study found that long-term use of PPI and H2RA was not associated with incident dementia, cognitive impairment without dementia (CIND), or decline in cognition over time.
Article
Medicine, General & Internal
Niklas Worm Andersson, Rasmus Huan Olsen, Jon Traerup Andersen
Summary: This nationwide cohort study found that the use of macrolide antibiotics during pregnancy was not associated with an increased risk of major birth defects. Analyses of 12 specific subgroups of birth defects also did not show a significant association with the use of macrolides.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Gastroenterology & Hepatology
Qiangsheng He, Bin Xia, Wenbo Meng, Die Fan, Zi-Chong Kuo, Junjie Huang, Xiwen Qin, Huachun Zou, Yulong He, Changhua Zhang, Shuo Fang, Yihang Pan, Man Yang, Jinqiu Yuan
Summary: The study found that regular use of PPIs was not associated with an increased risk of all-cause mortality or cause-specific mortality, even after adjusting for confounding factors.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Oncology
Krisztian Homicsko, Reinhard Dummer, Christoph Hoeller, Jedd D. Wolchok, F. Stephen Hodi, James Larkin, Paolo A. Ascierto, Victoria Atkinson, Caroline Robert, Michael A. Postow, Sandra Re, David Paulucci, Darin Dobler, Olivier Michielin
Summary: This retrospective analysis examined the impact of proton pump inhibitors (PPIs) on the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma. The results showed insufficient evidence to support a meaningful association between PPI use and ICI efficacy.
Article
Cardiac & Cardiovascular Systems
Yue Ma, Shu Li, Hongxi Yang, Yuan Zhang, Huiping Li, Lihui Zhou, Jing Lin, Yanchun Chen, Yabing Hou, Xinyu Zhang, Tong Liu, Xin Zhou, Yaogang Wang
Summary: This study found that the use of proton pump inhibitors (PPIs) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), particularly among individuals without indications for medication. However, the use of histamine-2 receptor antagonists (H2RAs) is not related to the risk of ASCVD.
Review
Oncology
Tahmina Nasrin Poly, Ming-Chin Lin, Shabbir Syed-Abdul, Chih-Wei Huang, Hsuan-Chia Yang, Yu-Chuan (Jack) Li
Summary: The use of proton pump inhibitors (PPIs) is associated with an increased risk of gastric cancer. Patients who use PPIs have a higher risk of developing gastric cancer compared to non-users. This study highlights the need for careful consideration by clinicians when deciding to initiate or continue PPI therapy, especially in high-risk patients.
Editorial Material
Gastroenterology & Hepatology
Eun Jeong Gong, Hye-Kyung Jung
Summary: This article is related to the papers by Gong et al. To access these articles, visit and.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Peter Malfertheiner, Christian Schulz, Colin W. Howden
Summary: This article is related to Gong et al papers. To view these articles, visit the website.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Elizabeth T. Jensen, Joe Yi, Wesley Jackson, Rachana Singh, Robert M. Joseph, Karl C. K. Kuban, Michael E. Msall, Lisa Washburn, Rebecca Fry, Andrew M. South, T. Michael O'Shea
Summary: Early acid suppressant use in extremely preterm infants may be associated with poorer neurodevelopmental outcomes, including decreased IQ scores, autism spectrum disorder, and epilepsy.
Editorial Material
Endocrinology & Metabolism
Peter Ueda, Henrik Svanstrom, Anders Hviid, Bjorn Eliasson, Ann-Marie Svensson, Stefan Frazen, Soffia Gudbjornsdottir, Kristian Hveem, Christian Jonasson, Viktor Wintzell, Mads Melbye, Bjorn Pasternak
Article
Cardiac & Cardiovascular Systems
Oystein Karlstad, Petteri Hovi, Anders Husby, Tommi Harkanen, Randi Marie Selmer, Nicklas Pihlstrom, Jorgen Vinslov Hansen, Hanna Nohynek, Nina Gunnes, Anders Sundstrom, Jan Wohlfahrt, Tuomo A. Nieminen, Maria Grunewald, Hanne Lovdal Gulseth, Anders Hviid, Rickard Ljung
Summary: Results of this large cohort study indicated that both first and second doses of mRNA vaccines were associated with an increased risk of myocarditis and pericarditis, especially in males aged 16 to 24. These findings are important for vaccine recipients and highlight the need to balance the risks and benefits of COVID-19 vaccination.
Article
Allergy
Stine Skovbo Hoffmann, Emilia Myrup Thiesson, Jeanne Duus Johansen, Anders Hviid
Summary: This study identified several risk factors for vaccination granulomas at the vaccine, child, and maternal levels. Reducing the dose of aluminium or replacing aluminium hydroxide with aluminium phosphate could reduce the risk of granulomas.
CONTACT DERMATITIS
(2022)
Article
Multidisciplinary Sciences
Anna Irene Vedel Sorensen, Lampros Spiliopoulos, Peter Bager, Nete Munk Nielsen, Jorgen Vinslov Hansen, Anders Koch, Inger Kristine Meder, Steen Ethelberg, Anders Hviid
Summary: A considerable number of individuals infected with SARS-CoV-2 continue to experience symptoms after the acute phase. Dysosmia, dysgeusia, fatigue/exhaustion, dyspnea, and reduced strength in arms/legs were the most commonly reported symptoms. Anxiety and depression diagnoses were also more common among test-positive individuals. Being female or middle-aged increases the risk of experiencing these symptoms.
NATURE COMMUNICATIONS
(2022)
Editorial Material
Pediatrics
Paula L. Hedley, Marie Baekvad-Hansen, Gitte Hedermann, Henrik Hjalgrim, David M. Hougaard, Mads Melbye, Morten Breindahl, Lone Krebs, Anders Hviid, Ulrik Lausten-Thomsen, Michael Christiansen
Article
Endocrinology & Metabolism
Arvid Engstroem, Viktor Wintzell, Mads Melbye, Anders Hviid, Bjoern Eliasson, Soffia Gudbjoernsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanstroem, Bjoern Pasternak, Peter Ueda
Summary: Using nationwide registers data from Denmark, Norway, and Sweden, this study demonstrates an association between the use of SGLT2 inhibitors and the risk of new-onset atrial fibrillation. Compared to GLP-1 receptor agonists, SGLT2 inhibitors are associated with a modestly reduced risk of new-onset atrial fibrillation.
Correction
Multidisciplinary Sciences
Nete Munk Nielsen, Thor Gronborg Junker, Sanne Grundvad Boelt, Arieh S. Cohen, Kassandra L. Munger, Egon Stenager, Alberto Ascherio, Lasse Boding, Anders Hviid
SCIENTIFIC REPORTS
(2023)
Article
Cardiac & Cardiovascular Systems
Carl-Emil Lim, Bjorn Pasternak, Bjorn Eliasson, Goodarz Danaei, Peter Ueda
Summary: This study investigated the proportion of patients with type 2 diabetes in Sweden who were recommended treatment with SGLT2 inhibitors and GLP-1 receptor agonists according to two European clinical guidelines. Depending on the guideline used, between half and 80% of the patients were recommended treatment with either drug, but only one in three or one in four actually received the recommended treatment.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Obstetrics & Gynecology
Aya O. Nakitanda, Helle Kieler, Ingvild Odsbu, Samuel Rhedin, Catarina Almqvist, Bjorn Pasternak, Laura Pazzagli
Summary: Prenatal antibiotic use increases the risk of childhood infections in the first year of life, but is not associated with infant mortality due to infections. The association between prenatal antibiotic exposure and infant infections may be partly explained by shared familial factors and does not differ across different antibiotic classes.
AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM
(2023)
Article
Public, Environmental & Occupational Health
Peter Ueda, Bjorn Pasternak, Carl-Emil Lim, Martin Neovius, Manzur Kader, Magnus Forssblad, Jonas F. Ludvigsson, Henrik Svanstroem
Summary: A cohort study reveals that male football players in the Swedish top division have a significantly higher risk of neurodegenerative disease, especially Alzheimer's disease and other dementias. The study provides important data for assessing and managing risks in the sport.
LANCET PUBLIC HEALTH
(2023)
Letter
Medicine, General & Internal
Anders Hviid
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Medicine, General & Internal
Niklas Worm Andersson, Emilia Myrup Thiesson, Jorgen Vinslov Hansen, Anders Hviid
Summary: This study examined the risk of adverse events associated with the fourth dose of omicron adapted bivalent mRNA COVID-19 booster vaccines. It found that there was no significant increase in the rate of adverse events among adults aged 50 years or older.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Meeting Abstract
Public, Environmental & Occupational Health
Aya Nakitanda, Helle Kieler, Ingvild Odsbu, Samuel Rhedin, Catarina Almqvist, Bjorn Pasternak, Laura Pazzagli
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2022)
Meeting Abstract
Public, Environmental & Occupational Health
Arvid Engstrom, Victor Wintzell, Mads Melbye, Henrik Svanstrom, Bjorn Eliasson, Soffia Gudbjornsdottir, Kristian Hveem, Christian Jonasson, Anders Hviid, Bjorn Pasternak, Peter Ueda
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2022)
Meeting Abstract
Public, Environmental & Occupational Health
Arvid Engstrom, Victor Wintzell, Mads Melbye, Anders Hviid, Bjorn Eliasson, Soffia Gudbjornsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanstrom, Bjorn Pasternak, Peter Ueda
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2022)